Life Sciences Review recognizes the pure-play lentiviral vector company’s work to help Asia-Pacific healthcare providers manufacture CAR-T therapies closer to patients.

GAITHERSBURG, Md., Nov. 9, 2026 — Vector BioMed, a leading lentiviral vector supplier and contract vector development and manufacturing organization (CVDMO), today announced that it has been named Lentiviral Vector Design and Manufacturing Company of the Year in Asia 2026 by Life Sciences Review. The recognition highlights the company’s specialized lentiviral vector expertise and its work helping healthcare providers around the world develop and deliver advanced cell and gene therapies closer to where patients live. [Read more…]